$CYCN
Cyclerion Therapeutics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021003724 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $533.0K $348.0K $3.000M
YoY Change 310.0% -13.0% 300.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.413M $4.601M $6.241M
YoY Change -39.3% -42.7% -5.87%
% of Gross Profit
Research & Development $10.46M $7.032M $12.05M
YoY Change -13.5% -48.68% -12.61%
% of Gross Profit
Depreciation & Amortization $48.00K $48.00K $116.0K
YoY Change -89.79% -91.86% -80.98%
% of Gross Profit
Operating Expenses $14.87M $11.63M $19.18M
YoY Change -23.19% -47.55% 39.02%
Operating Profit -$11.29M -$16.18M
YoY Change -48.19%
Interest Expense -$1.000K -$5.000K -$6.000K
YoY Change -105.56% -104.29%
% of Operating Profit
Other Income/Expense, Net -$5.000K -$6.000K
YoY Change -105.38% -104.35%
Pretax Income -$10.78M -$11.29M -$16.18M
YoY Change -43.97% -39.98% -17.14%
Income Tax
% Of Pretax Income
Net Earnings -$10.78M -$11.29M -$16.18M
YoY Change -43.97% -39.99% -17.16%
Net Earnings / Revenue -2021.58% -3244.25% -539.4%
Basic Earnings Per Share -$0.26
Diluted Earnings Per Share -$248.4K -$260.8K -$453.2K
COMMON SHARES
Basic Shares Outstanding 43.32M 43.29M
Diluted Shares Outstanding 43.29M

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $53.96M $62.50M $70.39M
YoY Change -0.81% -6.43% 24.58%
Cash & Equivalents $53.96M $62.50M $70.39M
Short-Term Investments
Other Short-Term Assets $468.0K $459.0K $2.599M
YoY Change -85.2% -72.45% 8.29%
Inventory
Prepaid Expenses $928.0K $562.0K
Receivables $100.0K $158.0K $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $55.46M $63.68M $72.99M
YoY Change -5.2% -9.19% 22.46%
LONG-TERM ASSETS
Property, Plant & Equipment $65.00K $112.0K $153.0K
YoY Change -99.05% -98.9% -99.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.407M $2.499M $2.590M
YoY Change -13.2% -12.77% -59.53%
Total Long-Term Assets $3.874M $4.060M $2.743M
YoY Change -93.19% -93.37% -95.99%
TOTAL ASSETS
Total Short-Term Assets $55.46M $63.68M $72.99M
Total Long-Term Assets $3.874M $4.060M $2.743M
Total Assets $59.33M $67.74M $75.73M
YoY Change -48.58% -48.45% -40.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.828M $1.174M $1.386M
YoY Change 59.09% -13.68% -46.69%
Accrued Expenses $8.759M $5.839M $5.393M
YoY Change -25.77% -44.92% -40.08%
Deferred Revenue
YoY Change
Short-Term Debt $3.500M $3.509M $3.509M
YoY Change 0.0% 0.26% 0.26%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.09M $11.36M $10.51M
YoY Change -34.61% -30.17% -32.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.09M $11.36M $10.51M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $11.09M $11.36M $10.51M
YoY Change -80.17% -79.72% -83.02%
SHAREHOLDERS EQUITY
Retained Earnings -$215.1M -$204.3M -$193.0M
YoY Change 31.6% 41.68%
Common Stock $263.3M $260.7M $258.3M
YoY Change 18.12% 18.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $48.25M $56.39M $65.22M
YoY Change
Total Liabilities & Shareholders Equity $59.33M $67.74M $75.73M
YoY Change -48.58% -48.45% -40.83%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income -$10.78M -$11.29M -$16.18M
YoY Change -43.97% -39.99% -17.16%
Depreciation, Depletion And Amortization $48.00K $48.00K $116.0K
YoY Change -89.79% -91.86% -80.98%
Cash From Operating Activities -$8.630M -$7.923M -$5.504M
YoY Change -38.53% -47.36% -61.29%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$7.000K $0.00
YoY Change -100.0% -30.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $4.000K
YoY Change -100.0% -100.0% -60.0%
Cash From Investing Activities $0.00 -$7.000K $4.000K
YoY Change -100.0% -106.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 85.00K 43.00K 30.63M
YoY Change -46.87% -99.82% 736.8%
NET CHANGE
Cash From Operating Activities -8.630M -7.923M -5.504M
Cash From Investing Activities 0.000 -7.000K 4.000K
Cash From Financing Activities 85.00K 43.00K 30.63M
Net Change In Cash -8.545M -7.887M 25.13M
YoY Change -31.31% -185.54% -336.6%
FREE CASH FLOW
Cash From Operating Activities -$8.630M -$7.923M -$5.504M
Capital Expenditures $0.00 -$7.000K $0.00
Free Cash Flow -$8.630M -$7.916M -$5.504M
YoY Change -38.4% -47.37% -61.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Defined Contribution Plan Type Extensible List
DefinedContributionPlanTypeExtensibleList
us-gaap:QualifiedPlanMember
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001755237
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38787
dei Entity Registrant Name
EntityRegistrantName
CYCLERION THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1895370
dei Entity Address Address Line1
EntityAddressAddressLine1
245 First Street, 18th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
327-8778
dei Security12b Title
Security12bTitle
Common Stock, no par value
dei Trading Symbol
TradingSymbol
CYCN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43315745
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62503000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54395000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
158000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2021Q3 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
0
CY2020Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
127000
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
562000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
816000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
459000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3163000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
63682000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
58501000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
0
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3837000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
112000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6865000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1449000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43402000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2499000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2773000
CY2021Q3 us-gaap Assets
Assets
67742000
CY2020Q4 us-gaap Assets
Assets
115378000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1174000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1149000
CY2021Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
0
CY2020Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
286000
CY2021Q3 cycn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
3432000
CY2020Q4 cycn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1421000
CY2021Q3 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
3240000
CY2020Q4 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
7294000
CY2021Q3 us-gaap Notes Payable Current
NotesPayableCurrent
3509000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3509000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3293000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11355000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16952000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38933000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43310089
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43310089
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34047300
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34047300
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-204300000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-163429000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
260713000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
222949000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-26000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-27000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
56387000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
59493000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67742000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115378000
CY2021Q3 cycn Revenue From License
RevenueFromLicense
0
CY2020Q3 cycn Revenue From License
RevenueFromLicense
0
cycn Revenue From License
RevenueFromLicense
3000000
cycn Revenue From License
RevenueFromLicense
0
CY2021Q3 cycn Revenue From Development Agreement
RevenueFromDevelopmentAgreement
77000
CY2020Q3 cycn Revenue From Development Agreement
RevenueFromDevelopmentAgreement
0
cycn Revenue From Development Agreement
RevenueFromDevelopmentAgreement
138000
cycn Revenue From Development Agreement
RevenueFromDevelopmentAgreement
0
CY2021Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
us-gaap Lease Cost
LeaseCost
6900000
CY2020Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
400000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2163000
CY2021Q3 cycn Revenue From Grant
RevenueFromGrant
271000
CY2020Q3 cycn Revenue From Grant
RevenueFromGrant
0
cycn Revenue From Grant
RevenueFromGrant
271000
cycn Revenue From Grant
RevenueFromGrant
0
CY2021Q3 us-gaap Revenues
Revenues
348000
CY2020Q3 us-gaap Revenues
Revenues
400000
us-gaap Revenues
Revenues
3409000
us-gaap Revenues
Revenues
2163000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7032000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13703000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27178000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44322000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4601000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8033000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16207000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21551000
CY2021Q3 cycn Gain Loss On Modification Of Lease
GainLossOnModificationOfLease
-0
CY2020Q3 cycn Gain Loss On Modification Of Lease
GainLossOnModificationOfLease
-444000
cycn Gain Loss On Modification Of Lease
GainLossOnModificationOfLease
-881000
cycn Gain Loss On Modification Of Lease
GainLossOnModificationOfLease
1669000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
11633000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
22180000
us-gaap Operating Expenses
OperatingExpenses
44266000
us-gaap Operating Expenses
OperatingExpenses
64204000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11285000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21780000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40857000
us-gaap Operating Income Loss
OperatingIncomeLoss
-62041000
CY2021Q3 cycn Sublease Termination Income Loss Net
SubleaseTerminationIncomeLossNet
0
CY2020Q3 cycn Sublease Termination Income Loss Net
SubleaseTerminationIncomeLossNet
2875000
cycn Sublease Termination Income Loss Net
SubleaseTerminationIncomeLossNet
0
cycn Sublease Termination Income Loss Net
SubleaseTerminationIncomeLossNet
2875000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
93000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
592000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11290000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-18812000
us-gaap Net Income Loss
NetIncomeLoss
-40872000
us-gaap Net Income Loss
NetIncomeLoss
-58574000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.08
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.01
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43291000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32096000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37730000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29196000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11290000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-18812000
us-gaap Net Income Loss
NetIncomeLoss
-40872000
us-gaap Net Income Loss
NetIncomeLoss
-58574000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-0
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-7000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-11290000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-18809000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-40871000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-58581000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
97729000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-20228000
CY2020Q1 cycn Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans
StockIssuedDuringPeriodValueExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans
1000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4036000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
81540000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-19534000
CY2020Q2 cycn Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans
StockIssuedDuringPeriodValueExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans
155000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3952000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
66101000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-18812000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
24250000
CY2020Q3 cycn Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans
StockIssuedDuringPeriodValueExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans
16000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3796000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
75354000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
59493000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13399000
CY2021Q1 cycn Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans
StockIssuedDuringPeriodValueExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans
27000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1921000
CY2021Q1 cycn Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees
SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees
391000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
48433000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16182000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30497000
CY2021Q2 cycn Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans
StockIssuedDuringPeriodValueExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans
133000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1942000
CY2021Q2 cycn Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees
SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees
398000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
65222000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11290000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6000
CY2021Q3 cycn Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans
StockIssuedDuringPeriodValueExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans
37000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2018000
CY2021Q3 cycn Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees
SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees
394000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-0
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
56387000
us-gaap Profit Loss
ProfitLoss
-40872000
us-gaap Profit Loss
ProfitLoss
-58574000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
424000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1827000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-6322000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-205000
cycn Gain Loss On Lease Modification And Termination
GainLossOnLeaseModificationAndTermination
-881000
cycn Gain Loss On Lease Modification And Termination
GainLossOnLeaseModificationAndTermination
1669000
cycn Sublease Termination Income Loss Net
SubleaseTerminationIncomeLossNet
0
cycn Sublease Termination Income Loss Net
SubleaseTerminationIncomeLossNet
2875000
us-gaap Share Based Compensation
ShareBasedCompensation
7064000
us-gaap Share Based Compensation
ShareBasedCompensation
11785000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
158000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-127000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-1074000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-254000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-748000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1254000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
8000
cycn Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
105000
cycn Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
3592000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-274000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
979000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
25000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1094000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-286000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
414000
cycn Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
2011000
cycn Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-38000
cycn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1048000
cycn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2000000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-4054000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-3673000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27887000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58449000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1489000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1464000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
71000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1457000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3837000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62503000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1800000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
6300000
CY2021Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1418000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
30503000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
24250000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
197000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
172000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3509000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30700000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27931000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-7000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4271000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31943000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58232000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
102620000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62503000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70677000
cycn Payments For Lease Modification Termination Fee And Other Initial Direct Costs
PaymentsForLeaseModificationTerminationFeeAndOtherInitialDirectCosts
0
cycn Payments For Lease Modification Termination Fee And Other Initial Direct Costs
PaymentsForLeaseModificationTerminationFeeAndOtherInitialDirectCosts
6507000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62503000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66840000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70677000
us-gaap Health Care Trust Fund Description
HealthCareTrustFundDescription
We have initiated our CY6463 Phase 2a clinical trial in adult participants with MELAS. Startup activities are ongoing for our Phase 2a clinical trial in ADv, with enrollment expected to begin in 2021.The ADv study will be supported in part by a grant from the Alzheimer’s Association’s Part the Cloud-Gates Partnership Grant Program ("PTC Grant"), which provides Cyclerion with $2 million of funding over two years
CY2019Q2 cycn Dividends Common Stock Stock Ratio
DividendsCommonStockStockRatio
0.1
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preparation of consolidated financial statements in accordance with U.S. GAAP requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. On an ongoing basis, the Company’s management evaluates its estimates, judgments, and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue, impairment of long-lived assets, valuation procedures for right-of-use assets and operating lease liabilities, income taxes, including the valuation allowance for deferred tax assets, research and development expenses, contingencies, share-based compensation and going concern. The Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">bases </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2265000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17152000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2153000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10287000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
112000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6865000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2021Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
957000
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1720000
CY2021Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
450000
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
514000
CY2021Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
338000
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
555000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
503000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
689000
CY2021Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
159000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3640000
CY2021Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
833000
CY2020Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
176000
CY2021Q3 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
3240000
CY2020Q4 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
7294000
CY2020Q3 us-gaap Lease Cost
LeaseCost
2000000.0
cycn Decrease In Right Of Use Assets Related To Lease Modification
DecreaseInRightOfUseAssetsRelatedToLeaseModification
42058000
cycn Decrease In Right Of Use Assets Related To Lease Modification
DecreaseInRightOfUseAssetsRelatedToLeaseModification
27333000
cycn Decrease In Operating Lease Liabilities Related To Lease Modification
DecreaseInOperatingLeaseLiabilitiesRelatedToLeaseModification
41177000
cycn Decrease In Operating Lease Liabilities Related To Lease Modification
DecreaseInOperatingLeaseLiabilitiesRelatedToLeaseModification
29002000
us-gaap Operating Lease Payments
OperatingLeasePayments
6076000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y9M18D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.061
CY2020Q3 cycn Rentable Square Feet Terminated From Lease Agreement
RentableSquareFeetTerminatedFromLeaseAgreement
15700
CY2021Q3 cycn Sublease Termination Agreement Estimated Fair Value Of Rooms
SubleaseTerminationAgreementEstimatedFairValueOfRooms
1500000
CY2021Q3 cycn Sublease Termination Agreement Estimated Fair Value Of Services
SubleaseTerminationAgreementEstimatedFairValueOfServices
2900000
CY2021Q3 cycn Sublease Termination Agreement Prepaid Rooms And Services
SubleaseTerminationAgreementPrepaidRoomsAndServices
4400000
CY2021Q3 cycn Prepaid Rooms Balance Related To Other Assets
PrepaidRoomsBalanceRelatedToOtherAssets
1400000
CY2021Q3 cycn Lease Expense Term
LeaseExpenseTerm
P8Y10M17D
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2412000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3796000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7064000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11784000
cycn Ptc Grant Award
PtcGrantAward
2000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
150000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.01
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
450000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.01
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M1D
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11290000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-18812000
us-gaap Net Income Loss
NetIncomeLoss
-40872000
us-gaap Net Income Loss
NetIncomeLoss
-58574000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43291000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32096000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37730000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29196000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.08
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.01
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.75
cycn Defined Contribution Plan Employer Matching Contribution Maximum
DefinedContributionPlanEmployerMatchingContributionMaximum
6000
CY2021Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000
CY2020Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
400000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
400000
CY2021Q3 cycn Allowable Expenses On Grant Revenue
AllowableExpensesOnGrantRevenue
300000
cycn Allowable Expenses On Grant Revenue
AllowableExpensesOnGrantRevenue
300000
CY2021Q3 us-gaap Deferred Revenue
DeferredRevenue
400000

Files In Submission

Name View Source Status
0000950170-21-003724-index-headers.html Edgar Link pending
0000950170-21-003724-index.html Edgar Link pending
0000950170-21-003724.txt Edgar Link pending
0000950170-21-003724-xbrl.zip Edgar Link pending
cycn-20210930.htm Edgar Link pending
cycn-20210930.xsd Edgar Link pending
cycn-20210930_cal.xml Edgar Link unprocessable
cycn-20210930_def.xml Edgar Link unprocessable
cycn-20210930_htm.xml Edgar Link completed
cycn-20210930_lab.xml Edgar Link unprocessable
cycn-20210930_pre.xml Edgar Link unprocessable
cycn-ex31_1.htm Edgar Link pending
cycn-ex31_2.htm Edgar Link pending
cycn-ex32_1.htm Edgar Link pending
cycn-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending